Soligenix Inc. Warrant (SNGXW) Stock Analysis
DELISTED 2021
What happened to Soligenix Inc. Warrant (SNGXW) stock?
Soligenix Inc. Warrant (SNGXW) no longer trades on public markets. It was delisted in December 2021. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Soligenix Inc. Warrant (SNGXW) trades at $0.009. Soligenix Inc. Warrant (SNGXW) operates within the healthcare sector, specifically in biotechnology. As a warrant, its value is derived from the underlying common stock of Soligenix, Inc. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for SNGXW: SNGXW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNGXW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Soligenix Inc. Warrant (SNGXW) Healthcare & Pipeline Overview
Soligenix Inc. Warrant (SNGXW) is a derivative security in the biotechnology sector, offering exposure to the potential upside of Soligenix, Inc.'s common stock. The warrant's value is intrinsically linked to the performance and prospects of Soligenix's pipeline of therapeutic products and its overall financial health within the competitive biotech landscape.
What Is the Investment Thesis for SNGXW?
An investment in Soligenix Inc. Warrant (SNGXW) is a leveraged bet on the success of Soligenix, Inc. The warrant's value is directly tied to the price of the underlying common stock, making it a higher-risk, higher-reward investment. Key value drivers include positive clinical trial results for Soligenix's lead product candidates, regulatory approvals from the FDA and other agencies, and successful commercial launches. Upcoming data readouts from ongoing clinical trials represent significant catalysts. However, potential risks include clinical trial failures, regulatory setbacks, and the need for additional capital, which could dilute existing shareholders. The warrant's expiration date also plays a crucial role, as it limits the time horizon for potential gains.
Based on FMP financials and quantitative analysis
SNGXW Key Highlights
P/E ratio of -0.48, reflecting the company's current lack of profitability.
- Beta of 1.61, indicating higher volatility compared to the overall market.
- No dividend yield, as the company is focused on reinvesting earnings into research and development.
- Dependence on successful clinical trials for pipeline advancement.
- Exposure to regulatory risk associated with drug approval processes.
Who Are SNGXW's Competitors?
SNGXW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNGXW's Key Strengths?
Focus on rare diseases with unmet medical needs.
- Proprietary formulation and delivery technologies.
- Experienced management team.
- Late-stage product candidates with potential for near-term approval.
What Are SNGXW's Weaknesses?
Dependence on successful clinical trial outcomes.
- Reliance on regulatory approvals.
- Limited commercial infrastructure.
- Need for additional capital to fund operations.
What Could Drive SNGXW Stock Higher?
Data readouts from ongoing clinical trials for SGX301 in CTCL.
- Potential FDA approval of SGX301 for CTCL.
- Development of oral mucositis treatment (SGX942).
- Leveraging the ThermoVax® platform for vaccine development.
- Pursuit of government funding and grants for research and development.
What Are the Key Risks for SNGXW?
Clinical trial failures for lead product candidates.
- Regulatory setbacks and delays in approval processes.
- Competition from other companies developing therapies for similar indications.
- Need for additional capital, which could dilute existing shareholders.
- Dependence on intellectual property protection.
What Are the Growth Opportunities for SNGXW?
- Ongoing clinical trials and potential FDA approval in the near future could drive substantial growth.
- Development of oral mucositis treatment (SGX942): Oral mucositis is a common and debilitating side effect of cancer therapy, creating a substantial market for effective treatments. Positive clinical trial results and subsequent commercialization of SGX942 could generate significant revenue for Soligenix. The timeline for potential approval is dependent on clinical trial progress.
- Leveraging the ThermoVax® platform for vaccine development: The ThermoVax® platform has the potential to create thermostable vaccines that do not require refrigeration, addressing a critical need in developing countries. This could open up new markets and revenue streams for Soligenix. Development timelines depend on research progress and partnerships.
- Expanding the pipeline through strategic acquisitions or collaborations: Soligenix could acquire or partner with other companies to expand its pipeline and diversify its product offerings. This could accelerate growth and reduce reliance on its existing product candidates. The timing and success of such initiatives are uncertain.
- Securing government funding and grants for research and development: Soligenix could pursue government funding and grants to support its research and development efforts. This could reduce the company's financial burden and accelerate the development of its product candidates. The availability and success of grant applications are variable.
What Are SNGXW's Competitive Advantages?
- Patents protecting its proprietary formulations and technologies.
- Regulatory exclusivity for approved products.
- Specialized expertise in rare disease drug development.
- Established relationships with key opinion leaders and healthcare providers.
What Does SNGXW Do?
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where significant unmet medical needs exist. While the warrant (SNGXW) itself is not the operating entity, it represents the right to purchase shares of Soligenix, Inc.'s common stock under specific terms. Soligenix's pipeline includes therapies targeting areas such as cutaneous T-cell lymphoma (CTCL), oral mucositis, and pediatric Crohn's disease. The company's approach involves leveraging its expertise in formulation and delivery technologies to improve the efficacy and safety profiles of existing and novel compounds. Soligenix's success is dependent on the successful completion of clinical trials, regulatory approvals, and subsequent commercialization of its product candidates. The company operates primarily in the United States, with potential for global expansion as its products gain regulatory clearance in other markets. Soligenix faces competition from other biotechnology and pharmaceutical companies developing therapies for similar indications.
What Products and Services Does SNGXW Offer?
- Develops and commercializes therapies for rare diseases.
- Focuses on areas with unmet medical needs.
- Utilizes expertise in formulation and delivery technologies.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approvals from the FDA and other agencies.
- Commercializes approved products through its sales and marketing infrastructure.
- Manages intellectual property and patents related to its products.
How Does SNGXW Make Money?
- Develops pharmaceutical products through research and development.
- Conducts clinical trials to prove safety and efficacy.
- Seeks regulatory approval to market and sell products.
- Generates revenue through product sales after approval.
What Industry Does SNGXW Operate In?
Soligenix operates within the highly competitive biotechnology industry, characterized by intense research and development, lengthy regulatory approval processes, and significant capital requirements. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. Soligenix competes with both large pharmaceutical companies and smaller biotech firms developing treatments for similar indications. Market trends include increasing demand for targeted therapies, advancements in drug delivery technologies, and a growing emphasis on personalized medicine. The biotechnology industry is subject to stringent regulatory oversight and faces challenges related to intellectual property protection and pricing pressures.
Who Are SNGXW's Key Customers?
- Patients suffering from rare diseases.
- Healthcare providers who prescribe Soligenix's products.
- Hospitals and clinics that administer Soligenix's therapies.
- Government agencies and payers that reimburse for Soligenix's products.
Company Profile
Soligenix Inc. Warrant operates in the Biotechnology industry within the Healthcare sector. SNGXW has traded publicly since 2016.
SNGXW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting optimism around upcoming clinical trial results.
- The company's focus on rare diseases aligns with growing market demand for specialized treatments, attracting attention from investors.
- Recent partnerships and collaborations have strengthened its position in the biotech sector, enhancing credibility and potential for growth.
Bear Case
- Concerns over the company's cash runway have surfaced, raising questions about its ability to sustain operations without additional funding.
- Social media sentiment remains mixed, with some investors expressing skepticism about the viability of its pipeline.
- Market perception of biotech stocks has been cautious, influenced by broader economic uncertainty and regulatory challenges.
- Insider selling activity has also been noted, which can signal a lack of confidence among some stakeholders in the company's short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SNGXW Latest News
No recent news available for SNGXW.
Leadership: None
CEO title
Unknown
Track Record: Unknown
What Investors Ask About Soligenix Inc. Warrant (SNGXW) — Healthcare
What happened to Soligenix Inc. Warrant (SNGXW) stock?
Soligenix Inc. Warrant (SNGXW) no longer trades on public markets. It was delisted in December 2021. The figures below are historical and are not a current quote.
Can I still buy SNGXW shares?
No. SNGXW stopped trading on public markets in December 2021, so the shares are not available through a broker. Anything you see quoted for SNGXW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SNGXW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Soligenix Inc. Warrant. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Soligenix Inc. Warrant represent and how is its value derived?
Soligenix Inc. Warrant (SNGXW) represents the right to purchase shares of Soligenix, Inc.'s common stock at a specified price within a specific timeframe. Its value is entirely derived from the underlying common stock's price; as the common stock price increases above the warrant's exercise price, the warrant's value appreciates.
What are the key clinical programs that will drive Soligenix's value and, consequently, the warrant's value?
Soligenix's value is significantly tied to the success of its key clinical programs, including SGX301 for cutaneous T-cell lymphoma (CTCL) and SGX942 for oral mucositis. Positive clinical trial results, regulatory approvals, and successful commercialization of these products are critical value drivers.
What are the main risks associated with investing in Soligenix Inc. Warrant?
Investing in Soligenix Inc. Warrant carries significant risks, primarily related to the uncertainty of clinical trial outcomes, regulatory hurdles, and the company's financial position. Clinical trial failures or regulatory setbacks could negatively impact the price of the underlying common stock, potentially rendering the warrant worthless.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis is based on limited information available for Soligenix Inc. Warrant.
- The biotechnology industry is inherently risky and subject to rapid changes.
- Investment decisions should be based on thorough research and consultation with a financial advisor.